Condition: Hemophilia A With Inhibitor · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.
This description comes directly from the study's public registry record.
Wei Liu · +8613820261971 · liuwei1@ihcams.ac.cn
Lei Zhang · zhanglei1@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05888870